Comparative Pharmacology
Head-to-head clinical analysis: GYNE SULF versus SULFADIAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE SULF versus SULFADIAZINE.
GYNE-SULF vs SULFADIAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GYNE-SULF (sulfisoxazole) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth.
Competitive inhibitor of dihydropteroate synthase, blocking the synthesis of folic acid in bacteria.
Intravaginal: One full applicator (approximately 5 g of 2% cream, containing 100 mg sulfanilamide) inserted intravaginally once daily (at bedtime) for 7-10 days. Alternatively, one vaginal suppository (containing 250 mg sulfanilamide) inserted intravaginally twice daily (morning and bedtime) for 7-10 days.
Oral: 2-4 g initially, then 1 g every 4-6 hours for mild to moderate infections; for severe infections, 4 g initially followed by 1.5 g every 4 hours. IV: Not available in IV form in the US; if using oral suspension, adjust accordingly.
None Documented
None Documented
Clinical Note
moderateSulfadiazine + Gatifloxacin
"Sulfadiazine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfadiazine + Rosoxacin
"Sulfadiazine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfadiazine + Levofloxacin
"Sulfadiazine may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSulfadiazine + Trovafloxacin
"Sulfadiazine may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life: 10-12 hours (normal renal function). In renal impairment (CrCl <30 mL/min): up to 24-48 hours.
Terminal elimination half-life 10-20 hours (prolonged in renal impairment; may require dose adjustment)
Renal: 80% (unchanged). Biliary/fecal: 15% as metabolites. Metabolized by reduction and acetylation; parent and metabolites undergo glomerular filtration and active tubular secretion.
Renal excretion of unchanged drug (50-70%) and acetylated metabolites; minor biliary/fecal (<5%)
Category C
Category D/X
Sulfonamide Antibiotic
Sulfonamide Antibiotic